0000921895-20-002557.txt : 20201007
0000921895-20-002557.hdr.sgml : 20201007
20201007194755
ACCESSION NUMBER: 0000921895-20-002557
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201004
FILED AS OF DATE: 20201007
DATE AS OF CHANGE: 20201007
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Graham Camilla
CENTRAL INDEX KEY: 0001827543
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36866
FILM NUMBER: 201229896
MAIL ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Summit Therapeutics Inc.
CENTRAL INDEX KEY: 0001599298
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-514-7149
MAIL ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Therapeutics plc
DATE OF NAME CHANGE: 20150219
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Corp plc
DATE OF NAME CHANGE: 20140205
4
1
form412566002_10072020.xml
OWNERSHIP DOCUMENT
X0306
4
2020-10-04
0
0001599298
Summit Therapeutics Inc.
SMMT
0001827543
Graham Camilla
ONE BROADWAY
14TH FLOOR
CAMBRIDGE
MA
02142
0
1
0
0
Chief Clinical Affairs Officer
Stock Option (right to buy)
3.34
2020-10-04
4
A
0
400000
3.34
A
2030-10-04
Common Stock
400000
400000
D
The option was granted on October 4, 2020 pursuant to the Company's 2020 Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 4, 2021, subject to the satisfaction of certain performance targets.
/s/ Michael Paul Donaldson, Attorney-in-Fact
2020-10-07